BioSpace News Archive

Keele, UK, 31 March 2020: Cobra Biologics, an international CDMO for biologics and pharmaceuticals, announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19, for fast-tracked clinical trials for COVID-19.

Following close on the heels of its vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.

Software provider Accruent announced today that it is offering newly-developed resources to hospitals and medical facilities to assist the healthcare industry in combatting the COVID-19 pandemic

Disgraced pharma executive Martin Shkreli is pleading to be temporarily let out of prison in order to join in the fight against COVID-19, the disease that has swept across the globe infecting more than 1.3 million people across the globe.

Empirical Bioscience announced that their QuanTASE and QuanTASE PLUS One Step RT-qPCR RT-qPCR Kits have been successfully tested in assays using EUA authorized qPCR detection kits using the established CDC testing protocol.

Menlo Therapeutics released topline results from two Phase III trials of once daily oral serlopitant for pruritus (itching) associated with prurigo nodularis. Neither trial met their primary endpoint.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.

The research was presented at the Revolutionizing Atopic Dermatitis Virtual Symposium.

“Today’s announcement marks a significant milestone towards fulfilling our promise to patients globally with TNBC of providing a new treatment option that can meaningfully improve their lives,” said Behzad Aghazadeh, executive chairman of Immunomedics.

After nearly five years at Alkermes, Lisa von Moltke has left the company and taken a new position as chief medical officer of Seres Therapeutics.